Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production

Stifel Defends Horizon Therapeutics (HZNP)

Stifel analyst Annabel Samimy came out to defend Horizon Therapeutics (NASDAQ: HZNP), saying Tepezza supply disruptions are a timing problem and said patient warehousing should bring a strong recovery.

The firm reiterated a Buy rating and $108.00 price target on HZNP.

For an... More

Horizon Therapeutics (HZNP) Tepezza Shortage 'Seems Manageable' - BMO

BMO Capital analyst Gary Nachman reiterated an Outperform rating and $110.00 price target on Horizon Therapeutics (NASDAQ: HZNP), saying while the short-term Tepezza shortage to due COVID is unfortunate, it "seems manageable."

The analyst commented, "HZNP disclosed short-term Tepezza shortage from manufacturers capacity... More